Boehringer Ingelheim and Eli Lilly and Company plan to conduct two outcome trials investigating the diabetes medicine Jardiance (empagliflozin) for the treatment of people with chronic heart failure. The trials are targeted to begin within the next 12 months and are planned to enroll people with chronic heart failure both with and without Type 2 diabetes.

Jardiance, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, was approved by the US Food and Drug Administration in 2014 as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. It was developed as part of the diabetes alliance formed between Boehringer Ingelheim and Eli Lilly in 2011.

Source: Eli Lilly and Company